Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | GYS1 | P13807 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 2/20 | 0.30 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026512 | 0.90 | NPC1 (0.41) | NPC1TNFRAB9ANOD1MC4R | |
| SCHEMBL5636044 | 0.87 | MC4R (0.39) | NPC1MC4RKDM2BEEDNTRK1 | |
| SCHEMBL4021139 | 0.87 | KDM2B (0.43) | NPC1TNFRAB9ANOD1MC4R | |
| SCHEMBL4779145 | 0.87 | MC4R (0.40) | NPC1TNFRAB9ANOD1MC4R | |
| SCHEMBL4779138 | 0.87 | MC4R (0.40) | NPC1TNFRAB9ANOD1MC4R | |
| SCHEMBL4020633 | 0.84 | MEN1 (0.35) | MC4RKDM2B | |
| SCHEMBL4749122 | 0.83 | KDR (0.35) | KDM2BKDR | |
| SCHEMBL4027446 | 0.83 | OPRM1 (0.35) | KIF11KCNH2KDM2B | |
| SCHEMBL4027439 | 0.83 | OPRM1 (0.35) | KIF11KCNH2KDM2B | |
| SCHEMBL4029041 | 0.83 | KDM4E (0.38) | KDM2BKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | NPC1 263/4885TNF 3755/4885RAB9A 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.